QUANTITATIVE ESTIMATE has-miR-16-5p, has-miR-425-5p, has-miR-17-5p, has-miR-20a-5p, has-miR-101-3p, has-miR-30D-5p AND has-miR-93-5p IN PERIPHERAL BLOOD PLASMA OF WOMEN AS METHOD FOR NON-INVASIVE DIAGNOSIS OF SEROUS BOUNDARY OVARY ADENOCYSTOMA AND CYSTADENOCARCENOMA

QUANTITATIVE ESTIMATE has-miR-16-5p, has-miR-425-5p, has-miR-17-5p, has-miR-20a-5p, has-miR-101-3p, has-miR-30D-5p AND has-miR-93-5p IN PERIPHERAL BLOOD PLASMA OF WOMEN AS METHOD FOR NON-INVASIVE DIAGNOSIS OF SEROUS BOUNDARY OVARY ADENOCYSTOMA AND CYSTADENOCARCENOMA

FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to oncogynecology, and aims at non-invasive diagnosis of serous adenocystoma borderline and high-grade ovarian cystadenocarcinoma. Disclosed is a quantitative estimate of hsa-miR-16-5p, hsa-miR-425-5p, hsa-miR-17-5p, hsa-miR-20a-5...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Khabas Grigorij Nikolaevich, Sukhikh Gennadij Tikhonovich, Sannikova Majya Viktorovna, Frankevich Vladimir Evgenevich, Asaturova Aleksandra Vyacheslavovna, Chagovets Vitalij Viktorovich, Timofeeva Anzhelika Vladimirovna
Format: Patent
Sprache:eng ; rus
Schlagworte:
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
TESTING
VINEGAR
WINE
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to oncogynecology, and aims at non-invasive diagnosis of serous adenocystoma borderline and high-grade ovarian cystadenocarcinoma. Disclosed is a quantitative estimate of hsa-miR-16-5p, hsa-miR-425-5p, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-101-3p, hsa-miR-30d-5p and hsa-miR-93-5p in peripheral blood plasma of females. Quantitative real-time PCR in a blood plasma sample of a woman is used to determine the level of expression of seven mRNA (hsa-miR-16-5p, hsa-miR-425-5p, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-101-3p, hsa-miR-30d-5p and hsa-miR-93-5p) with preferable use of standard DNA for subsequent calculation of the estimation parameter (EP) when constructing the PLS-DA model. If value is 0 < EP